HGH Fragment 176-191 is a small piece of human growth hormone — literally the last 16 amino acids of the hormone, the "tail." The idea behind it is neat: growth hormone helps the body burn fat, and researchers traced that fat-burning action to this specific tail. So the fragment is marketed as a way to get the fat-loss effect without the rest of growth hormone. Here is the honest headline most websites bury: almost everything known about it comes from mice, not people.
In plain terms: a promising fat-burning idea from animal studies that has never really been proven in humans.
What it is
Human growth hormone is a 191-amino-acid protein. In the 1990s and 2000s, researchers narrowed its fat-burning ("lipolytic") activity down to the very end of the molecule — the region spanning amino acids 176 to 1911. HGH Fragment 176-191 is a synthetic copy of just that stretch.
Two features made it interesting as a fat-loss candidate. First, in studies the fragment burned fat much like the full hormone did. Second, it did this without the parts of growth hormone people worry about: it did not raise blood sugar, did not increase IGF-1 (a growth signal), and did not compete for the growth-hormone receptor1. The fat-burning action, in effect, seemed to travel with the tail.
Its close relative, AOD-9604, is essentially this same fragment with one extra amino acid (tyrosine) added for stability — and AOD-9604 is the version that actually reached human clinical testing.
How it is thought to work
The proposed mechanism is lipolysis — the breakdown of stored fat into usable energy. In animal and cell studies, the fragment increased activity of the beta-3 adrenergic receptor (beta-3-AR), the main "burn fat" switch on fat cells2.
The strongest evidence for that mechanism is a knockout experiment done with the AOD-9604 analog: the fat-loss effect was present in normal mice but vanished in mice engineered to lack the beta-3 receptor2. Remove the switch, and the effect disappears — which is a convincing way to show the switch matters.
In plain terms: in animals, it appears to turn on the fat-burning machinery of fat cells. But note the honesty flag — this is an animal and cell result, not a demonstrated human effect.
What the studies actually found
The evidence base for the fragment is short and almost entirely preclinical. The one large body of human data belongs to its analog, AOD-9604 — and that data is sobering. Note the model in each row:
| Study | Model | Key result | Year |
|---|---|---|---|
| Ng et al.1 | Mouse + cell studies | Isolated the 176-191 lipolytic domain; the fragment burned fat like growth hormone but without raising blood sugar | 2000 |
| Heffernan et al.2 | Obese mice + beta-3-AR knockout mice | Reduced body fat via the beta-3 receptor; effect disappeared without that receptor | 2001 |
| Stier et al. (AOD-9604 analog)3 | Human (6 trials, 900+ people) | The stabilised analog was safe in people — but its largest obesity trial did not beat placebo on weight loss | 2013 |
The pattern is consistent and worth stating plainly: encouraging fat-loss results in mice, and no convincing human fat-loss result for the fragment. The nearest thing to a human test — the AOD-9604 analog — was safe but failed its main efficacy trial3.
The honest catch: an animal story marketed as a human one
This is the part vendor pages blur, so here it is directly:
- What the science shows: a plausible fat-burning mechanism through the beta-3 receptor, demonstrated in mice and cells2.
- What it does not show: that injecting the fragment causes meaningful fat loss in people. There are essentially no controlled human fat-loss trials of HGH Fragment 176-191 itself, and its closest human-tested analog failed its obesity endpoint3.
So "HGH Fragment 176-191 is a fat-loss peptide" is a claim resting almost entirely on animal biology. That does not make the animal results uninteresting — it means the human proof is missing, and you deserve to hear that plainly.
Pharmacokinetics
The fragment is a small peptide with no albumin anchor or other long-acting modification, so it is short-acting — cleared from the blood quickly, on the order of minutes rather than the days seen with weekly drugs like cagrilintide. Precise, well-replicated human half-life figures for the fragment are not established, which itself reflects how thin the human data is.
Regulatory status
HGH Fragment 176-191 is not an approved medicine for fat loss or any other use. It is a research compound. This page explains what it is and what studies show — not how to use it — and it takes no position on sourcing.
Latest research
- The foundational mouse and cell work from 2000-2001 remains the core of the evidence base, and it is still what any fat-burning claim traces back to12.
- The most relevant human signal is negative: the stabilised analog AOD-9604 was tested in people and did not deliver weight loss in its largest trial3.
- No large controlled human trial of the fragment itself has changed this picture. We update this section as new studies land.
The short version
HGH Fragment 176-191 is the fat-burning "tail" of human growth hormone, synthesised on its own. In mice it triggered fat breakdown through the beta-3 receptor, without growth hormone's blood-sugar effects. But its evidence is almost entirely preclinical — the fragment has essentially no human fat-loss trials, and its close analog AOD-9604 failed its largest human obesity study. It is a research compound, not a proven fat-loss medicine. Educational overview only, not medical advice.